心脏转甲状腺素蛋白淀粉样变性症状前闪烁显像与遗传级联筛查
2020至2024年前瞻性纳入100例转甲状腺素蛋白淀粉样变性(ATTR)患者的无症状亲属,无论预测发病年龄均行临床评估、基因检测、超声心动图及[99mTc]Tc-DPD闪烁显像与SPECT/CT级联筛查。闪烁显像在8.2%亲属中检出心脏淀粉样变性(CA),20.5%携带致病性转甲状腺素蛋白变异但无放射性示踪剂摄取,Phe53Leu最常见;野生型ATTR患者亲属均无CA且未携带变异。新诊断ATTR CA亲属高敏肌钙蛋白升高,病理性Q波、室间隔与左室后壁增厚、TDI侧壁与室间隔E'速度降低及「5-5-5」征发生率更高(p < 0.05)。
要点
- 闪烁显像在8.2%的无症状亲属中检出心脏淀粉样变性。
- 20.5%亲属携带致病性转甲状腺素蛋白变异但无示踪剂摄取,以Phe53Leu为主。
- 野生型ATTR患者亲属均未见心脏淀粉样变性且未携带变异。
核心结论
- 整合遗传与闪烁显像的系统筛查方案有助于ATTR的早期检出。
- 相当比例遗传性ATTR患者的无症状亲属可能存在潜在心脏淀粉样变性。
研究设计与样本
- 2020至2024年前瞻性研究,连续纳入100例成人无症状ATTR患者亲属。
- 采用多模态级联筛查,包括临床数据、基因检测、超声心动图、闪烁显像及[99mTc]Tc-DPD SPECT/CT,不论预测发病年龄。
- 注册号ClinicalTrials.gov Identifier: NCT05814380。
主要发现
- 闪烁显像在8.2%的亲属中检出心脏淀粉样变性。
- 20.5%的亲属携带致病性转甲状腺素蛋白变异但无放射性示踪剂摄取,以Phe53Leu为主。
- 野生型ATTR患者的亲属均无闪烁显像心脏淀粉样变性,也未携带转甲状腺素蛋白变异。
- 新诊断ATTR心脏淀粉样变性的亲属高敏肌钙蛋白升高,病理性心电图Q波、室间隔与左室后壁增厚、TDI侧壁与室间隔E'速度降低及「5-5-5」征的发生率更高(p < 0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: While early diagnosis is crucial, as new treatments can significantly slow the progression of the disease, there is growing evidence on the application of novel imaging techniques for detecting transthyretin amyloidosis (ATTR) in pre-symptomatic stages. This study aimed to evaluate the utility of pre-symptomatic scintigraphic imaging cascade screening for early detection of ATTR. METHODS: During the period from 2020 to 2024, we conducted a prospective study that enrolled 100 consecutive adults. The study utilized a multimodal cascade screening approach to assess asymptomatic relatives of individuals with ATTR (ClinicalTrials.gov Identifier: NCT05814380). The analysis incorporated clinical data, genetic testing, echocardiography, scintigraphy and single-photon emission computed tomography/computed tomography (SPECT/CT) with [99mTc]Tc-DPD, regardless of the predicted age of disease onset. RESULTS: Overall, scintigraphy identified cardiac amyloidosis (CA) in 8.2% of relatives, while 20.5% carried a pathogenic transthyretin variant without radiotracer uptake, with Phe53Leu being predominant. Notably, no relatives of wild-type ATTR patients exhibited CA on scintigraphy or carried a transthyretin variant. Additionally, newly-diagnosed relatives with ATTR CA presented elevated high-sensitivity troponin levels and exhibited a higher incidence of pathological electrocardiographic Q waves, greater thickness of the intraventricular septum and left ventricular posterior wall, a notable decline in lateral wall and intraventricular septal E' tissue velocities measured by TDI, and the "5-5-5" sign (p < 0.05). CONCLUSION: The presented findings demonstrate that implementing a systematic screening protocol, which integrates genetic and scintigraphic testing, facilitates the early detection of ATTR. Crucially, a significant proportion of asymptomatic relatives of patients with hereditary ATTR may suffer from underlying CA. REGISTRATION: ClinicalTrials.gov Identifier: NCT05814380.
引用
- Holcman K, Rubiś P, Ćmiel B, et al. Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis. Eur J Nucl Med Mol Imaging. 2024. PMID: 39537877. doi:10.1007/s00259-024-06966-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。